Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Avinger (AVGR) and GlycoMimetics (GLYC)
GlycoMimetics | 10-Q: Q2 2024 Earnings Report
GlycoMimetics Announces Strategic Review and Restructuring Plan
Express News | GlycoMimetics Inc - Employment of Edwin Rock, Co's Chief Medical Officer, Will End on July 31, 2024
Express News | GlycoMimetics Inc: Anticipates Recognizing About $3.6 Mln in Total Charges in Connection With Headcount Reduction
Express News | GlycoMimetics Inc - Restructuring That Includes a Reduction in Company's Workforce by 26 Employees, or Approximately 80% of Its Headcount
TD Cowen Downgrades GlycoMimetics to Hold
GlycoMimetics Analyst Ratings
TD Cowen Downgrades GlycoMimetics to Hold From Buy
Express News | GlycoMimetics Inc : TD Cowen Cuts to Hold From Buy
TD Cowen Downgrades GlycoMimetics(GLYC.US) to Hold Rating
TD Cowen analyst Tara Bancroft downgrades $GlycoMimetics(GLYC.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 54.1% and a total average return of 28.7% over the
GlycoMimetics (GLYC) Was Downgraded to a Hold Rating at TD Cowen
Predictive POAI AI/ML Platform Expansion; GlycoMimetics GLYC Strategic Review
GlycoMimetics: Strategic Overhaul and FDA Setback Justify Hold Rating
H.C. Wainwright Remains a Hold on GlycoMimetics (GLYC)
GlycoMimetics To Conduct Additional Clinical Trial For Uproleselan In R/R Acute Myeloid Leukemia After FDA Meeting; Initiates Strategic Review And Corporate Restructuring, Reducing Workforce By 80%; Engages Lucid Capital Markets As Strategic Advisor;...
Express News | GlycoMimetics Inc - FDA Requires Additional Trial for Uproleselan in Aml
Express News | GlycoMimetics Inc - Cash Expected to Fund Company Into Q2 2025
Express News | GlycoMimetics Inc: Will Reduce Its Workforce by Approximately 80%
Express News | GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan